Business Context and Reporting Period
This Form 8-K Current Report was filed by Cerecor Inc. on December 27, 2018, reporting events occurring on December 26 and 27, 2018. The company is an emerging growth company incorporated in Delaware. The filing details a material definitive agreement and unregistered sales of equity securities involving a significant stockholder, Armistice Capital Master Fund Ltd. (Armistice).
Key Financial Metrics and Transaction Details
- Proceeds Raised: Approximately $5.7 million received from Armistice for the purchase of Series B Non-Voting Convertible Preferred Stock.
- Securities Issued:
- 2,857,143 shares of Series B Non-Voting Convertible Preferred Stock (exercise price $2.00 per share).
- Warrants to purchase 4,000,000 shares of common stock (New Warrant) with a 5.5-year term and an exercise price of $12.50 per share.
- Warrant Exchange: A prior warrant to purchase 14,285,714 common shares (exercise price $0.40) was exchanged for the warrant to purchase the Series B Preferred Stock.
- Use of Proceeds: General corporate purposes.
- Financial Statements: This filing does not contain revenue, profit, cash flow, or margin data. It is a transactional report.
Material Changes and Corporate Actions
The primary material change is the capital raise and restructuring of equity instruments with Armistice. Key actions include:
- Early Exercise: Armistice agreed to early exercise the Exchanged Warrant to acquire the Series B Preferred Stock.
- Stock Designation: The company filed a Certificate of Designation for the Series B Preferred Stock. These shares convert to common stock on a 1-for-5 ratio and carry no voting rights.
- Registration Rights: The company agreed to file a registration statement within 30 days of the closing to register the resale of common stock underlying the New Warrant.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking guidance, management commentary on operations, or specific risk factors beyond standard legal disclosures. Notable contingencies and restrictions include:
- Resale Restrictions: The New Warrant and underlying common stock may not be offered or sold in the United States absent registration or an exemption under the Securities Act of 1933.
- Transaction Exemption: The issuance of the New Warrant relied on Section 4(a)(2) of the Securities Act as an exemption from registration.
- No Intermediaries: No placement agent or underwriter was involved in the offering.
Investor Verification Checklist
- Verify the conversion ratio (1-for-5) and non-voting status of the newly issued Series B Preferred Stock.
- Confirm the filing of the registration statement for the resale of the 4,000,000 shares underlying the New Warrant within the required 30-day window.
- Review the full text of the Securities Purchase Agreement and Registration Rights Agreement (Exhibits 10.1 and 10.2) for covenants not summarized in this report.
- Assess the impact of the $5.7 million cash infusion on the company's liquidity and runway, given the lack of operating revenue data in this filing.